Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 
Adetola  Kassim

Adetola Kassim, M.D., M.S.

Associate Professor of Medicine (Hematology/Oncology)
Director, Adult Sickle Cell Disease Program
Clinical Director, Adult Stem Cell Transplant Program
Hematologist/Oncologist

  • Appointments
    615-936-8422
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Vanderbilt University Medical Center
    (615) 322-5000

    Office
    615-936-3851
  • Faxes

    Clinic Fax
    615-936-1812
  • Addresses
    Clinic
    1301 Medical Center Drive
    3903 The Vanderbilt Clinic
    Nashville, TN 37232-5505

    Vanderbilt University Medical Center
    1211 Medical Center Drive
    Nashville, TN 37232
    Website

    Office
    Division of Hematology/Oncology
    3927 The Vanderbilt Clinic
    1301 Medical Center Dr.
    Nashville, TN 37232-5505
Profile

Dr. Kassim specializes in hematology and hematopoietic stem cell transplantation. His clinical research efforts is focused on harnessing the use of stem cell transplant technology in improving patient care outcomes, both for hematologic malignancies (such as leukemias, lymphomas and myelomas) as well as benign hematologic disorders such a sickle cell disease, aplastic anemias and bone marrow failure states.
Read more...

Dr. Kassim specializes in hematology and hematopoietic stem cell transplantation. His clinical research efforts is focused on harnessing the use of stem cell transplant technology in improving patient care outcomes, both for hematologic malignancies (such as leukemias, lymphomas and myelomas) as well as benign hematologic disorders such a sickle cell disease, aplastic anemias and bone marrow failure states.

He directs the adult sickle cell disease program, and in conjunction with the Department of Pediatrics at Vanderbilt Childrens Hospital and Meharry Medical Center, have helped develop a Sickle Cell Disease Center of Excellence to address the need of patients and families affected by the disorder. Research in the area of sickle cell disease focuses mainly on the study of epigenetic determinants of disease expression, development of a patient centered medical home model of care and use of evidence based management paradigms to improve both patient satisfaction and care outcomes. He is investigating the use of alternate donor and reduced intensity hematopoietic stem cell transplant approaches as a curative modality for the disease.

Education
  • Internal Medicine- Mount Sinai Hospital Program, New York, NY.
  • Hematology/Oncology- Albert Einstein College of Medicine, Montefiore Medical cencer, Bronx, New York
  • Bone marrow Transplant- Johns Hopkins Hospital, Baltimore, Maryland
Research Description

Incidence of pulmonary hypertension in adult sickle cell patients. A prospective case-controlled study.

Publications
  • Kassim AA, Galadanci NA, Pruthi S, DeBaun MR. How I treat and manage strokes in sickle cell disease. Blood [print-electronic]. 2015 May 5/28/2015; 125(22): 3401-10. PMID: 25824688, PMCID: PMC4467906, PII: blood-2014-09-551564, DOI: 10.1182/blood-2014-09-551564, ISSN: 1528-0020.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25824688.
  • Wolf RB, Saville BR, Roberts DO, Fissell RB, Kassim AA, Airewele G, DeBaun MR. Factors associated with growth and blood pressure patterns in children with sickle cell anemia: Silent Cerebral Infarct Multi-Center Clinical Trial cohort. Am. J. Hematol [print-electronic]. 2015 Jan; 90(1): 2-7. PMID: 25236783, DOI: 10.1002/ajh.23854, ISSN: 1096-8652.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25236783.
  • Das-Gupta E, Greinix H, Jacobs R, Zhou L, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Jagasia M. Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure. Haematologica [print-electronic]. 2014 Nov; 99(11): 1746-52. PMID: 25150260, PMCID: PMC4222474, PII: haematol.2014.108217, DOI: 10.3324/haematol.2014.108217, ISSN: 1592-8721.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25150260.
  • Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez Viña M, Gratwohl A, Gupta V, Hanna R, Horowitz MM, Hurley CK, Inamoto Y, Kassim AA, Nishihori T, Mueller C, Oudshoorn M, Petersdorf EW, Prasad V, Robinson J, Saber W, Schultz KR, Shaw B, Storek J, Wood WA, Woolfrey AE, Anasetti C. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood [print-electronic]. 2014 Oct 10/16/2014; 124(16): 2596-606. PMID: 25161269, PMCID: PMC4199961, PII: blood-2014-05-576041, DOI: 10.1182/blood-2014-05-576041, ISSN: 1528-0020.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25161269.
  • Pauff JM, Gonzalez RS, Sajnani KP, Kassim A, Jagasia M. Post-allograft pomalidomide and reversible hepatotoxicity [letter]. Bone Marrow Transplant [print-electronic]. 2014 Oct; 49(10): 1341-2. PMID: 24955783, PII: bmt2014128, DOI: 10.1038/bmt.2014.128, ISSN: 1476-5365.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24955783.
  • Wolf RB, Kassim AA, Goodpaster RL, DeBaun MR. Nocturnal enuresis in sickle cell disease. Expert Rev Hematol. 2014 Apr; 7(2): 245-54. PMID: 24617333, DOI: 10.1586/17474086.2014.892412, ISSN: 1747-4094.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24617333.
  • Maheshwari S, Kassim A, Yeh RF, Domm J, Calder C, Evans M, Manes B, Bruce K, Brown V, Ho R, Frangoul H, Yang E. Targeted Busulfan therapy with a steady-state concentration of 600-700¿ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant. Bone Marrow Transplant [print-electronic]. 2014 Mar; 49(3): 366-9. PMID: 24317124, PII: bmt2013188, DOI: 10.1038/bmt.2013.188, ISSN: 1476-5365.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24317124.
  • Kassim AA, DeBaun MR. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. Expert Opin Pharmacother [print-electronic]. 2014 Feb; 15(3): 325-36. PMID: 24392871, DOI: 10.1517/14656566.2014.868435, ISSN: 1744-7666.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24392871.
  • Sengsayadeth S, Savani BN, Jagasia M, Goodman S, Greer JP, Chen H, Chinratanalab W, Kassim AA, Engelhardt BG. Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials. Bone Marrow Transplant [print-electronic]. 2014 Feb; 49(2): 236-40. PMID: 24096824, PMCID: PMC3946331, PII: bmt2013157, DOI: 10.1038/bmt.2013.157, ISSN: 1476-5365.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24096824.
  • Ragon BK, Clifton C, Chen H, Savani BN, Engelhardt BG, Kassim AA, Vaughan LA, Lucid C, Jagasia M. Geographic distance is not associated with inferior outcome when using long-term transplant clinic strategy. Biol. Blood Marrow Transplant [print-electronic]. 2014 Jan; 20(1): 53-7. PMID: 24120525, PII: S1083-8791(13)00450-3, DOI: 10.1016/j.bbmt.2013.10.004, ISSN: 1523-6536.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24120525.
  • Vaughan LA, Vu M, Sengsayadeth S, Lucid C, Clifton C, McCarty K, Hagaman D, Domm J, Kassim A, Chinratanalab W, Goodman S, Greer J, Frangoul H, Engelhardt BG, Jagasia M, Savani BN. New allergies after cord blood transplantation. Cytotherapy. 2013 Oct; 15(10): 1259-65. PMID: 23993300, PII: S1465-3249(13)00550-1, DOI: 10.1016/j.jcyt.2013.05.018, ISSN: 1477-2566.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23993300.
  • Jagasia M, Greinix H, Robin M, Das-Gupta E, Jacobs R, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Socie G. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol. Blood Marrow Transplant [print-electronic]. 2013 Jul; 19(7): 1129-33. PMID: 23623892, PII: S1083-8791(13)00186-9, DOI: 10.1016/j.bbmt.2013.04.018, ISSN: 1523-6536.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23623892.
  • Kassim AA, DeBaun MR. Sickle cell disease, vasculopathy, and therapeutics. Annu. Rev. Med [print-electronic]. 2013; 64: 451-66. PMID: 23190149, DOI: 10.1146/annurev-med-120611-143127, ISSN: 1545-326X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23190149.
  • Engelhardt BG, Sengsayadeth SM, Jagasia M, Savani BN, Kassim AA, Lu P, Shyr Y, Yoder SM, Rock MT, Crowe JE. Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival. Exp. Hematol [print-electronic]. 2012 Dec; 40(12): 974-982.e1. PMID: 22885125, PMCID: PMC3611587, PII: S0301-472X(12)00343-8, DOI: 10.1016/j.exphem.2012.08.002, ISSN: 1873-2399.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22885125.
  • Hart AJ, Jagasia MH, Kim AS, Mosse CA, Savani BN, Kassim A. Minimal residual disease in myeloma: are we there yet?. Biol. Blood Marrow Transplant [print-electronic]. 2012 Dec; 18(12): 1790-9. PMID: 22626785, PII: S1083-8791(12)00211-X, DOI: 10.1016/j.bbmt.2012.05.009, ISSN: 1523-6536.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22626785.
  • Sengsayadeth SM, Jagasia M, Engelhardt BG, Kassim A, Strickland SA, Goodman S, Lucid C, Vnencak-Jones CL, Greer JP, Savani BN. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant [print-electronic]. 2012 Dec; 47(12): 1535-7. PMID: 22659680, PII: bmt201288, DOI: 10.1038/bmt.2012.88, ISSN: 1476-5365.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22659680.
  • Jacobs R, Tran U, Chen H, Kassim A, Engelhardt BG, Greer JP, Goodman SG, Clifton C, Lucid C, Vaughan LA, Savani BN, Jagasia M. Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. Bone Marrow Transplant [print-electronic]. 2012 Nov; 47(11): 1470-3. PMID: 22484321, PII: bmt201256, DOI: 10.1038/bmt.2012.56, ISSN: 1476-5365.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22484321.
  • Chinratanalab W, Reddy N, Greer JP, Morgan D, Engelhardt B, Kassim A, Brandt SJ, Jagasia M, Goodman S, Savani BN. Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies. Exp. Hematol [print-electronic]. 2012 Jun; 40(6): 431-5. PMID: 22269114, PMCID: PMC4067702, PII: S0301-472X(12)00016-1, DOI: 10.1016/j.exphem.2012.01.014, ISSN: 1873-2399.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22269114.
  • Reddy N, Greer JP, Goodman S, Kassim A, Morgan DS, Chinratanalab W, Brandt S, Englehardt B, Oluwole O, Jagasia MH, Savani BN. Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. Exp. Hematol [print-electronic]. 2012 May; 40(5): 359-66. PMID: 22269117, PII: S0301-472X(12)00014-8, DOI: 10.1016/j.exphem.2012.01.012, ISSN: 1873-2399.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22269117.
  • Engelhardt BG, Jagasia SM, Crowe JE, Griffith ML, Savani BN, Kassim AA, Lu P, Weitkamp JH, Moore DJ, Yoder SM, Rock MT, Jagasia M. Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity. Blood [print-electronic]. 2012 Mar 3/8/2012; 119(10): 2417-21. PMID: 22262764, PMCID: PMC3311262, PII: blood-2011-10-384750, DOI: 10.1182/blood-2011-10-384750, ISSN: 1528-0020.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22262764.
  • Kassim AA, Fabry ME, Nagel RL. Acute priapism associated with the use of sildenafil in a patient with sickle cell trait. (Letter). Blood. 2000; 1;95((5)): 1878-9.
  • Kassim AA, Umans H, Nagel RL, Fabry ME. Megalophallus as a sequela of priapism in sickle cell anemia: use of blood oxygen level-dependent magnetic resonance imaging. Urology. 2000; 1;56((3)): 509.
  • Fabry, M.E., Liu, G., Kassim, A., Billet, H., Nagel, R.L. Deoxy HbS detection in brain of sickle cell disease patients by blood level oxygen dependent magnetic resonance imaging (BOLD-MRI). (Abstract). Blood. 1999; ((94)): 421a.
  • Fabry, M.E., Kassim, A., Umans, H., Nagel, R.L. Clinical applications of BOLD-MRI to extremities in sickle cell pain episodes. (Abstract). Blood. 1998; ((9, 92)): 525a.
  • Kassim, A., Sane, P., Billett, H. Tower skill or marrow expansion with pituitary hemosiderosis in beta thalassemia intermedia. Journal of Radiology.